{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"0"},{"groupId":"OG006","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"5"}]}],"title":"Partial Response"}],"denoms":[{"counts":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"13"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"11"}],"units":"Participants"}],"description":"ORR was defined as the percentage of participants having a complete response (CR) or partial response (PR) as determined by investigator assessment of radiographic disease per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.","groups":[{"description":"Epacadostat (Epa) oral twice-daily (BID) continuous daily dosing at the protocol-defined dose in combination with pembrolizumab administered intravenously (IV) in combination with mFOLFOX6 (oxaliplatin IV + leucovorin IV + 5-fluorouracil (5-FU) IV.","id":"OG000","title":"Group A: Epa + Pembrolizumab + mFOLFOX6"},{"description":"Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with nab-paclitaxel IV and gemcitabine IV.","id":"OG001","title":"Group B: Epa + Pembrolizumab + Nab-Paclitaxel and Gemcitabine"},{"description":"Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) in combination with paclitaxel IV and carboplatin IV.","id":"OG002","title":"Group C: Epa + Pembrolizumab + Paclitaxel and Carboplatin"},{"description":"Epa (100 mg) oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with pemetrexed IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.","id":"OG003","title":"Group D: Epa + Pembrolizumab + Pemetrexed and Platinum Agent"},{"description":"Epa (100 mg)oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab (200 mg) IV in combination with cyclophosphamide PO.","id":"OG004","title":"Group E: Epa + Pembrolizumab + Cyclophosphamide"},{"description":"Epa oral BID continuous daily dosing at the protocol-defined dose in combination with pembrolizumab IV in combination with gemcitabine IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.","id":"OG005","title":"Group F: Epa + Pembrolizumab + Gemcitabine and Platinum Agent"},{"description":"Epa oral BID continuousdaily dosing at the protocol-defined dose in combination with pembrolizumab IV in combination with 5-FU IV and Investigator's choice of platinum agent: carboplatin IV or cisplatin IV.","id":"OG006","title":"Group G: Epa + Pembrolizumab + 5-FU and Platinum Agent"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"The full analysis set included all participants enrolled in the study who received at least 1 dose of epacadostat and have at least 1 postbaseline assessment or who discontinued epacadostat.","reportingStatus":"POSTED","timeFrame":"Up to Week 18","title":"Phases 1 and 2: Objective Response Rate (ORR)","type":"PRIMARY","unitOfMeasure":"Participants"}